| Abbreviation | Full form |
| API | Active Pharmaceutical Ingredient |
| FDA | Food and Drug Administration |
| BCS | Biopharmaceutics Classification System |
| BBB | Blood Brain Barrier |
| IVIVC | In vitro In vivo Co-relationship |
| CYP450 | Cytochrome P450 |
| t1/2 | Biological half-life |
| TI | Therapeutic Index |
| TW | Therapeutic Window |
| MEC | Minimum effective concentration |
| PK | Pharmacokinetics |
| ED50 | Effective dose in 50% of subjects |
| TD50 | Toxic dose in 50% of subjects |
| DDS | Drug delivery systems |
| CRDDS | Controlled release drug delivery systems |
| EPR | Enhanced permeability and retention |
| PLK 1 | Serine/threonine-protein kinase |
| siRNA | Small interfering Ribose Nucleic acid |
| CNTs | Carbon nanotubes |
| SWCNTs | Single-walled carbon nanotubes |
| MWCNTs | Multiwalled carbon nanotubes |
| MMP | Matrix metallo proteinases |
| LCST | Lower critical solution temperature |
| MIP | Molecularly Imprinted Polymers |
| CRISPR Cas9 | Clustered regularly interspaced short palindromic repeats |
| sgRNA | Single guide RNA |
| LOC | Lab-on-a-chip |
| QD | Quantun dots |
| RES | Reticulo Endothelial system |